Recent Biotech News: MeiraGTx Reacquires Gene Therapy from J&J

MeiraGTx reacquired full rights to botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson/Janssen for $25 million upfront, plus a $50 million contingent milestone upon U.S. approval and sales exceeding $250 million, and mid-teens royalties starting mid-2029.1 2 3 5

The deal was announced on Thursday, allowing MeiraGTx to pursue regulatory approvals in the U.S. and EU in 2027 despite bota-vec missing its primary endpoint in the Phase 3 LUMEOS trial; the company sees supportive data for approval.1 2 4

Originally, J&J and MeiraGTx collaborated since 2019 in a deal worth up to $440 million, with J&J fully acquiring rights in 2023 after paying $130 million upfront.2 4

MeiraGTx also raised $100 million in an equity offering alongside the announcement.1

Note:
Search results focus extensively on the MeiraGTx deal with no specific details found on Storm Therapeutics' $56M Series C or Adlai Nortye's $150M funding.